Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut's existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.
Company profile
Ticker
KLDO
Exchange
Website
CEO
Daniel L. Menichella
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Cadena Bio, Inc. • Kaleido Biosciences Securities Corporation ...
KLDO stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
6 May 22
EFFECT
Notice of effectiveness
2 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Apr 22
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Apr 22
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Apr 22
POS AM
Prospectus update (post-effective amendment)
25 Apr 22
25
Voluntary exchange delisting
18 Apr 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Apr 22
NT 10-K
Notice of late annual filing
31 Mar 22
10-K
2021 FY
Annual report
31 Mar 22
Transcripts
Latest ownership filings
Financial summary
Quarter (USD) | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 40.64 mm | 40.64 mm | 40.64 mm | 40.64 mm | 40.64 mm | 40.64 mm |
Cash burn (monthly) | 5.73 mm | 645.67 k | 6.57 mm | 7.31 mm | 5.72 mm | 6.42 mm |
Cash used (since last report) | 158.22 mm | 17.84 mm | 181.39 mm | 201.81 mm | 158.01 mm | 177.47 mm |
Cash remaining | -117.58 mm | 22.80 mm | -140.75 mm | -161.17 mm | -117.37 mm | -136.83 mm |
Runway (months of cash) | -20.5 | 35.3 | -21.4 | -22.1 | -20.5 | -21.3 |
Institutional ownership, Q2 2022
28.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 0 |
Closed positions | 60 |
Increased positions | 0 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 128.37 mm |
Total shares | 12.09 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Flagship Ventures Fund V | 9.76 mm | $111.65 mm |
HarbourVest Partners | 1.83 mm | $16.69 mm |
Artal | 500.50 k | $31.00 k |
Captrust Financial Advisors | 129.00 | $0.00 |
Close Asset Management | 100.00 | $0.00 |